SCHEMBL2834258

SCHEMBL2834258

Cc1c(C(=O)O)c2cccc(F)c2c(=O)n1C(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
POLB P06746 4/20 0.37
HTT P42858 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
GPR139 Q6DWJ6 2/20 0.35
LMNA P02545 2/20 0.34
ATM Q13315 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
NOTUM Q6P988 1/20 0.33
PDE10A Q9Y233 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14828547 0.82 KDM4E (0.34) KDM4EGAAKMT2AMEN1POLB
SCHEMBL2830105 0.82 ATM (0.43) KDM4EGAAKMT2AMEN1CES2
SCHEMBL14828533 0.81 KMT2A (0.34) KDM4EGAAKMT2AMEN1GPR139
SCHEMBL2357893 0.81 MEN1 (0.34) KDM4EGAAKMT2AMEN1POLB
SCHEMBL2832018 0.81 KMT2A (0.39) KDM4EKMT2AMEN1POLBCES2
SCHEMBL14828543 0.80 F2RL1 (0.41) KMT2AMEN1
SCHEMBL14828541 0.80 ROCK2 (0.36) KDM4EGAAKMT2AMEN1GPR139
SCHEMBL14828558 0.80 TTR (0.34) KDM4EGAAKMT2AMEN1POLB
SCHEMBL2833409 0.80 KDM4E (0.49) KDM4EGAAKMT2AMEN1POLB
SCHEMBL3242977 0.79 SLC6A3 (0.34) KMT2AMEN1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 KDM4E 2545/4885GAA 1411/4885KMT2A 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.